From the prodromal stage of multiple sclerosis to disease prevention

被引:0
作者
Ruth Ann Marrie
Mark Allegretta
Lisa F. Barcellos
Bruce Bebo
Peter A. Calabresi
Jorge Correale
Benjamin Davis
Philip L. De Jager
Christiane Gasperi
Carla Greenbaum
Anne Helme
Bernhard Hemmer
Pamela Kanellis
Walter Kostich
Douglas Landsman
Christine Lebrun-Frenay
Naila Makhani
Kassandra L. Munger
Darin T. Okuda
Daniel Ontaneda
Ronald B. Postuma
Jacqueline A. Quandt
Sharon Roman
Shiv Saidha
Maria Pia Sormani
Jon Strum
Pamela Valentine
Clare Walton
Kathleen M. Zackowski
Yinshan Zhao
Helen Tremlett
机构
[1] University of Manitoba,Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences
[2] University of Manitoba,Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences
[3] National Multiple Sclerosis Society,Division of Epidemiology and Genetic Epidemiology and Genomics Laboratory, School of Public Health
[4] University of California Berkeley,Department of Neurology
[5] Kaiser Permanente Division of Research,Multiple Sclerosis Center, Center for Translational & Computational Neuroimmunology, Department of Neurology
[6] Johns Hopkins University School of Medicine,Department of Neurology, Klinikum rechts der Isar, TUM School of Medicine
[7] Departments of Neurology,Departments of Pediatrics and Neurology
[8] Neuroscience and Ophthalmology,Department of Nutrition
[9] Fleni,Department of Neurology
[10] Multiple Sclerosis Society of Canada,Department of Pathology and Laboratory Medicine, Faculty of Medicine
[11] Columbia University Irving Medical Center,Division of Neuroimmunology and Neurological Infections, Department of Neurology
[12] Technical University of Munich,Department of Health Sciences
[13] Center for Interventional Immunology and Diabetes Program,undefined
[14] Benaroya Research Institute,undefined
[15] Multiple Sclerosis International Federation,undefined
[16] Munich Cluster for Systems Neurology (SyNergy),undefined
[17] CHU de Nice Pasteur 2,undefined
[18] CRCSEP,undefined
[19] UR2CA-URRIS,undefined
[20] Université Nice Cote d’Azur Nice,undefined
[21] Yale School of Medicine,undefined
[22] Harvard TH Chan School of Public Health,undefined
[23] The University of Texas Southwestern Medical Center,undefined
[24] Department of Neurology,undefined
[25] Neuroinnovation Program,undefined
[26] Multiple Sclerosis and Neuroimmunology Imaging Program,undefined
[27] Mellen Center for Multiple Sclerosis Treatment and Research,undefined
[28] Cleveland Clinic,undefined
[29] McGill University,undefined
[30] University of British Columbia,undefined
[31] Patient representative,undefined
[32] Johns Hopkins University School of Medicine,undefined
[33] University of Genova,undefined
[34] and IRCCS Ospedale Policlinico San Martino,undefined
[35] RealTalk MS,undefined
[36] MS Society,undefined
[37] Faculty of Medicine (Neurology),undefined
[38] University of British Columbia,undefined
来源
Nature Reviews Neurology | 2022年 / 18卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
A prodrome is an early set of signs or symptoms that indicate the onset of a disease before more typical symptoms develop. Prodromal stages are well recognized in some neurological and immune-mediated diseases such as Parkinson disease, schizophrenia, type 1 diabetes mellitus and rheumatoid arthritis. Emerging evidence indicates that a prodromal stage exists in multiple sclerosis (MS), raising the possibility of intervention at this stage to delay or prevent the development of classical MS. However, much remains unclear about the prodromal stage of MS and considerable research is needed to fully characterize the prodrome and develop standardized criteria to reliably identify individuals with prodromal MS who are at high risk of progressing to a diagnosis of MS. In this Roadmap, we draw on work in other diseases to propose a disease framework for MS that incorporates the prodromal stage, and set out key steps and considerations needed in future research to fully characterize the MS prodrome, identify early disease markers and develop standardized criteria that will enable reliable identification of individuals with prodromal MS, thereby facilitating trials of interventions to slow or stop progression beyond the prodrome.
引用
收藏
页码:559 / 572
页数:13
相关论文
共 165 条
[1]  
Bjornevik K(2019)Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis JAMA Neurol. 80 616-624
[2]  
Cortese M(2016)Pre-clinical disease activity in multiple sclerosis: a prospective study on cognitive performance prior to first symptom Ann. Neurol. 83 1162-1173
[3]  
Disanto G(2018)Prodromal symptoms of multiple sclerosis in primary care Ann. Neurol. 14 293-300
[4]  
Marrie RA(2019)High rates of health care utilization in pediatric multiple sclerosis: a Canadian population-based study PLoS One 74 4758-4768
[5]  
Xia Z(2017)Assessment of early evidence of multiple sclerosis in a prospective study of asymptomatic high-risk family members JAMA Neurol. 129 445-451
[6]  
Beltrán E(2019)Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis J. Clin. Investig. 16 1526-1532
[7]  
Wijnands JMA(2017)Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study Lancet Neurol. 19 1600-1611
[8]  
Berger JR(2013)Fatigue heralding multiple sclerosis Mult. Scler. J. 30 779-788
[9]  
Pocoski J(2015)MDS research criteria for prodromal Parkinson’s disease Mov. Disord. 68 375-385
[10]  
Preblick R(2016)Preclinical rheumatoid arthritis: progress toward prevention Arthritis Rheumatol. 19 330-338